ENOVNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Enovis CORP
Financials through Q2 FY2026, quarter ended Jul 3, 2026Last filing: 10-Q on Aug 6, 2026
$19.87+0.28 (+1.43%)
Close on Oct 19, 2026
- Market cap
- $1.14B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$11.55 (−36.76%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Enovis CORP grew revenue 4.9% to $2.30B over the twelve months to Jul 3, 2026. Free cash flow was $63.66M.
Revenue
$2.30B
+4.9% vs. a year earlier
Operating income
-$1.04B
TTM Q2 2026
Free cash flow
$63.66M
TTM Q2 2026
EPS, diluted
-$19.26
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jul 3, 2026
Valuation
- Market cap
- $1.14B
- P/E ratio
- –
- Price to sales
- 0.50
- Price to book
- 0.77
- Dividend yield
- –
- Free cash flow yield
- 5.56%
Fundamentals
- Revenue
- $2.30B
- Net income
- -$1.10B
- EPS, diluted
- -$19.26
- Free cash flow
- $63.66M
- Book value per share
- $25.64
- Diluted shares
- 58M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
$2.30B+4.9% YoY
Gross profit
$1.40B+11.3% YoY
Operating income
-$1.04B
Net income
-$1.10B
EPS, diluted
-$19.26
Free cash flow
$63.66M
Reported periodTrailing twelve months